Skarping Ida, Brand Judith S, Hall Per, Borgquist Signe
Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Skåne University Hospital, SE-221 85, Lund, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
BMC Cancer. 2015 May 28;15:435. doi: 10.1186/s12885-015-1457-9.
Epidemiological data on statins and breast cancer risk have been inconclusive. The aim of this study was to clarify the role of statins in breast cancer risk by studying their effect on mammographic density.
The KARolinska MAmmography project for risk prediction of breast cancer (KARMA) includes 70,877 women who underwent either a screening or clinical mammography from January 2011 to December 2013. In total, 41,102 women responded to a web-based questionnaire, and had raw digital mammograms stored. Volumetric mammographic density was measured using Volpara™ and information on statin use was obtained through linkage with the Swedish National Prescription Register. Analysis of covariance was used to study the effect of statin use on mammographic density, adjusting for a large set of potential confounders. We also studied the effects of statin class and treatment duration and tested for potential effect modification by hormone replacement therapy (HRT).
Statin use was recorded in 3,337 women (8.1 %) of the study population and lipophilic statins was the most commonly prescribed type (93.4 % of all statin users). After multivariable adjustment, percent dense volume was lower in statin users than in non-users (P < 0.001). This association was explained by a larger absolute non-dense volume in statin users (P < 0.001). Overall, no difference in absolute dense volume was detected, but interaction analyses revealed a larger dense volume among statin users who reported ever HRT use (P = 0.03). No differential effects were observed according to statin lipophilicity and treatment duration.
We observed no overall effect of statin use on mammographic density in terms of absolute dense volume, although a larger absolute dense volume was observed in statin users who reported ever HRT use, which requires further investigation.
关于他汀类药物与乳腺癌风险的流行病学数据尚无定论。本研究的目的是通过研究他汀类药物对乳房X线密度的影响来阐明其在乳腺癌风险中的作用。
用于乳腺癌风险预测的卡罗林斯卡乳房X线摄影项目(KARMA)纳入了2011年1月至2013年12月期间接受筛查或临床乳房X线摄影的70877名女性。共有41102名女性回复了基于网络的问卷,并存储了原始数字乳房X线照片。使用Volpara™测量乳房X线体积密度,并通过与瑞典国家处方登记处的链接获取他汀类药物使用信息。采用协方差分析研究他汀类药物使用对乳房X线密度的影响,并对大量潜在混杂因素进行校正。我们还研究了他汀类药物类别和治疗持续时间的影响,并测试了激素替代疗法(HRT)的潜在效应修正作用。
研究人群中有3337名女性(8.1%)记录使用了他汀类药物,亲脂性他汀类药物是最常用的类型(占所有他汀类药物使用者的93.4%)。多变量调整后,他汀类药物使用者的致密体积百分比低于非使用者(P<0.001)。这种关联是由于他汀类药物使用者的绝对非致密体积更大(P<0.001)。总体而言,未检测到绝对致密体积的差异,但交互分析显示,报告曾使用HRT的他汀类药物使用者的致密体积更大(P=0.03)。根据他汀类药物的亲脂性和治疗持续时间未观察到差异效应。
就绝对致密体积而言,我们未观察到他汀类药物使用对乳房X线密度有总体影响,尽管报告曾使用HRT的他汀类药物使用者的绝对致密体积更大,这需要进一步研究。